Journal Watch · Frontiers in Immunology · 2026

Atypical X-linked agammaglobulinemia diagnosed in adulthood with arthritis caused by a hypomorphic BTK splice-site variant: a case report and literature review.

It also underscores the importance of integrating immunological and genetic evaluation with protein- and transcript-level analyses when interpreting atypical presentations and splice-site variants.

Takayama A, Meguro K, Yokota M et al.Frontiers in Immunology4 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1849090PMID: 42253969Study type: review / perspective

TL;DR

It also underscores the importance of integrating immunological and genetic evaluation with protein- and transcript-level analyses when interpreting atypical presentations and splice-site variants.

Key findings

  • Importantly, immunoglobulin replacement therapy was followed by sustained prevention of further deep infections and gradual improvement of synovitis, tenosynovitis, and skin manifestations.
  • This case highlights that common rheumatologic presentations in adults, such as arthritis, may mask an underlying IEI.
  • Early recognition of IEI can enable timely immunoglobulin replacement therapy, which may restore humoral immune protection, prevent further severe infections, and improve rheumatologic manifestations.
  • It also underscores the importance of integrating immunological and genetic evaluation with protein- and transcript-level analyses when interpreting atypical presentations and splice-site variants.

What they did

Genetic testing revealed a <i>BTK</i> splice-site variant, c.1103-2A>G (NM_000061.3). Functional analyses demonstrated abnormal splicing at the exon 12-13 junction, reduced <i>BTK</i> mRNA expression, and reduced but detectable BTK protein expression in monocytes, supporting residual protein expression consistent with a hypomorphic or leaky phenotype. Although XLA is generally considered to show limited genotype-phenotype correlation, residual BTK expression in this case could have contributed, at least in part, to the relatively mild early infectious phenotype. In addition, the patient's longstanding social withdrawal, with presumably limited exposure to infectious sources, may also have contributed to delayed clinical recognition until adulthood.

Full abstract (original)

Background: X-linked agammaglobulinemia (XLA) is an inborn error of immunity (IEI) caused by loss-of-function variants in the <i>Bruton tyrosine kinase</i> (<i>BTK</i>) gene, classically presenting in early childhood with recurrent bacterial infections. Here, we report an atypical case of XLA diagnosed in adulthood during evaluation of inflammatory arthritis. A 42-year-old man with no history of severe or recurrent infections initially presented with monoarticular inflammation of the right elbow joint and later developed Doppler-positive synovitis and tenosynovitis of the hands, together with a methicillin-sensitive Staphylococcus aureus lung abscess and a subsequent deep gluteal abscess. Immunological evaluation showed profound hypogammaglobulinemia with markedly reduced circulating B cells.

What they did: Genetic testing revealed a <i>BTK</i> splice-site variant, c.1103-2A>G (NM_000061.3). Functional analyses demonstrated abnormal splicing at the exon 12-13 junction, reduced <i>BTK</i> mRNA expression, and reduced but detectable BTK protein expression in monocytes, supporting residual protein expression consistent with a hypomorphic or leaky phenotype. Although XLA is generally considered to show limited genotype-phenotype correlation, residual BTK expression in this case could have contributed, at least in part, to the relatively mild early infectious phenotype. In addition, the patient's longstanding social withdrawal, with presumably limited exposure to infectious sources, may also have contributed to delayed clinical recognition until adulthood.

Results & conclusions: Importantly, immunoglobulin replacement therapy was followed by sustained prevention of further deep infections and gradual improvement of synovitis, tenosynovitis, and skin manifestations. This case highlights that common rheumatologic presentations in adults, such as arthritis, may mask an underlying IEI. Early recognition of IEI can enable timely immunoglobulin replacement therapy, which may restore humoral immune protection, prevent further severe infections, and improve rheumatologic manifestations. It also underscores the importance of integrating immunological and genetic evaluation with protein- and transcript-level analyses when interpreting atypical presentations and splice-site variants.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1849090 · PubMed 42253969.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

It also underscores the importance of integrating immunological and genetic evaluation with protein- and transcript-level analyses when interpreting atypical presentations and splice-site variants.

What type of study is this?

It is a review / perspective, published in Frontiers in Immunology in 2026. Genetic testing revealed a <i>BTK</i> splice-site variant, c.1103-2A>G (NM_000061.3).

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1849090. PubMed ID: 42253969. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Takayama A, Meguro K, Yokota M et al.. Atypical X-linked agammaglobulinemia diagnosed in adulthood with arthritis caused by a hypomorphic BTK splice-site variant: a case report and literature review.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1849090.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/atypical-x-linked-agammaglobulinemia-diagnosed-in-adulthood-with-arthrit-849090/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides